What BioCorteX does

BioCorteX is a London-based biotech company, founded in 2021, that builds computational tools to predict how an individual's microbiome will affect their response to a drug. Its core offering is the Carbon Mirror™ foundational emulator, which runs on top of Carbon Knowledge™, the world's largest biology-based microbiome knowledge graph (over 3 billion nodes and 16 billion edges, sourced from millions of samples across 165+ geopolitical regions, updated daily at a release cost typically under $30 and queried in under 10 seconds across a 435+ terabyte search space on Google Cloud's BigQuery). Carbon Mirror performs in-silico clinical trials that model the mechanistic interactions between bacteria, host immunity, metabolism, and pharmaceutical interventions, and is currently applied principally to Antibody-Drug Conjugates (ADCs) and immuno-oncology assets.

The company serves large pharmaceutical and biotechnology clients — most prominently Bayer, CD Biopharma (on the bispecific fusion protein CD-001), Tempus AI, and at least one unnamed publicly listed large pharma working on an ADC — through bespoke enterprise partnerships rather than self-serve licensing. Its go-to-market is direct enterprise field sales into pharma R&D teams, structured as multi-stage strategic collaborations that de-risk trial design, optimise patient stratification biomarkers, and support geographic asset transfer (e.g., China-to-global oncology assets). It is venture-backed (a ~$5.15M seed in March 2023 led by Hoxton Ventures and Sofinnova Partners, with a Merck Digital Sciences Studio grant) and operates from London, New York, and Adelaide, with scientific leadership recognition including the ASCO Conquer Cancer Award and peer-reviewed publications in the Journal of Investigative Dermatology, Nature conferences, ASCO and EACR.

Name

BioCorteX

Legal name

BioCorteX Ltd

Website

https://biocortex.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

BioCorteX is a London-based biotech that uses a proprietary microbiome knowledge graph (Carbon Knowledge) and foundational emulator (Carbon Mirror) to run in-silico clinical trials predicting drug-bacteria interactions. It serves large pharmaceutical and biopharma clients developing ADCs and immunotherapies via bespoke enterprise partnerships.

Ownership category

akta.pro rank

Product category

AI-driven Drug Discovery Software

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

Keywords

• Microbiome knowledge graph
• Drug-bacteria interaction analysis
• In silico clinical trials
• ADC development platform
• Tumour microbiome analytics

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Platform / Technology Licensing: BioCorteX provides pharmaceutical companies access to its Carbon Mirror platform for in silico drug testing, de-risking clinical trials, and optimizing trial design. Revenue is generated through partnership agreements and service contracts with pharma companies at various stages of drug development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

BioCorteX builds and operates Carbon Mirror, a foundational biology emulator layered on top of Carbon Knowledge, the world's largest biology-based microbiome knowledge graph. Together they predict drug-bacteria interactions in the tumour microenvironment and across populations, enabling in silico clinical trial emulation, biomarker discovery, and patient stratification for pharmaceutical companies developing ADCs, multispecific antibodies, and immunotherapies.

Product overview

BioCorteX offers a unified platform-plus-services architecture centered on two complementary core products: Carbon Knowledge (a large-scale microbiome knowledge graph with over 3 billion nodes) and Carbon Mirror (a foundational biology emulator). Carbon Mirror builds upon Carbon Knowledge to model and predict drug-bacteria interactions, clinical trial outcomes, and treatment responses through in-silico trials. The platform is enhanced by specialized ADC and bispecific antibody development services that apply these capabilities to de-risk pharmaceutical clinical trials and optimize patient stratification.

Differentiator

Problem solved

Functional benefit

Brands

• Carbon Knowledge™: An extraordinarily large biology-based knowledge graph with over 3bn nodes and 16bn edges, stored on BigQuery, containing the largest and most diverse collection of microbiome samples in existence.
• Carbon Mirror™

Products and services

• Carbon Knowledge The world's largest biology-based knowledge graph of microbiome samples, containing over 3 billion nodes and 16 billion edges sourced from millions of organic microbiome samples across 165+ geopolitical regions. Stored on BigQuery and updated with a new version published daily, typically under $30 per release. Used as the data substrate for the Carbon Mirror emulator and for direct biological knowledge retrieval by pharmaceutical R&D teams.
• Carbon Mirror A one-of-a-kind foundational biology emulator that builds upon Carbon Knowledge to uncover hidden mechanistic interactions between bacteria, the human immune system, diseases, and pharmaceutical interventions. Enables in silico clinical trial emulation across tumour types, regions, and patient communities, executing queries across a 435+ TB search space in under 10 seconds. Designed for pharmaceutical R&D teams developing ADCs, multispecific antibodies, and immunotherapies.
• ADC and Bispecific Antibody Development Services Specialised drug development services applying Carbon Mirror to de-risk Antibody-Drug Conjugate (ADC) and multispecific antibody (MsAb) clinical trials. Includes biomarker-driven trial design optimisation, geographic region-specific analysis, and patient stratification based on drug-bacteria interactions, delivered as bespoke partnership engagements for pharma and biotech clients.

Quantifiable outcome

• 30% increase in overall survival in silico for ADC trials using biomarker-driven patient stratification vs. standard trial design
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• CD BiopharmacoreStrategic or Co-development Partner · 24 November 2025BioCorteX announced a strategic collaboration with CD Biopharma, a leading Chinese biotechnology company, to develop next-generation precision immunotherapies for solid tumours. The partnership leverages BioCorteX's Carbon Mirror platform to test CD Biopharma's bispecific fusion protein CD-001 (anti-PD-1 + IL-21 mutant) in silico across different tumour types, regions, and patient communities. CD-001 has already received IND approvals from both the US FDA and China's NMPA. The collaboration aims to de-risk global clinical trial strategy and optimise the route to bringing life-changing treatments to patients worldwide, addressing regional variations in intra-tumour bacterial composition that affect immunotherapy response.
• Tempus AI, Inc.coreStrategic or Co-development Partner · 19 August 2024BioCorteX announced a collaboration with Tempus AI, Inc. (NASDAQ: TEM) to unlock the role of bacteria in the tumour microenvironment (TME) and create personalised patient profiles. The partnership combines Tempus's vast real-world data and AI platform with BioCorteX's Carbon Mirror foundational emulator to perform millions of in-silico trials. The initial focus is on triple-negative breast cancer, with plans to extend across wider cancer and disease areas. The collaboration aims to accelerate the development of novel insights throughout the therapeutic lifecycle and deliver truly personalised treatment regimes to patients.
• Google CloudcoreTechnology or IntegrationGoogle Cloud provides BioCorteX with scalable compute infrastructure, BigQuery data storage, Vertex AI Model Garden, and Gemini model capabilities. BioCorteX's Carbon Knowledge knowledge graph (3bn+ nodes, 16bn+ edges) is stored on BigQuery, and its Carbon Mirror foundational emulator leverages Google Cloud's infrastructure to process massive datasets rapidly and efficiently. Google Cloud has publicly identified BioCorteX as one of its biotechnology collaborators leveraging AI for drug discovery. Adrian Poole, Director Digital Natives UKI at Google Cloud, has issued public statements supporting BioCorteX's research.
• BayerminorStrategic or Co-development PartnerBayer is listed as a working partner of BioCorteX alongside Google Cloud and Nvidia. No specific details of the collaboration are provided on the website. Bayer logo appears in the 'Working in partnership with' section on the homepage.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Insitro: AI-driven drug discovery platform combining machine learning with high-throughput biology for pharma R&D. Most direct peer in terms of platform-based AI pharma services, though focused on broader disease biology rather than microbiome interactions specifically.
• Recursion Pharmaceuticals: Operates one of the largest AI-driven biology platforms for drug discovery, generating proprietary datasets at scale. Closely comparable business model — building a foundational data + ML platform sold to pharma partners — and operates at materially larger scale.
• Exscientia: AI-native pharma company that uses computational platforms to design and prioritize drug candidates in partnership with large pharma. Comparable as an enterprise pharma-facing AI drug discovery platform, though focused on molecule design rather than trial de-risking.
• CytoReason: AI platform that builds computational disease models from multi-omic and clinical data to support pharma R&D decision-making, particularly in immunology and oncology. Highly comparable use case (in-silico disease modeling for pharma) and customer base (top-20 pharma).
• Owkin: Federated AI platform applied to biomedical research and drug development, partnering with pharma using real-world patient data. Comparable as an AI-for-pharma platform targeting oncology R&D efficiency.

Broad incumbents

• Tempus AI: Publicly listed (NASDAQ: TEM) AI-enabled precision medicine company with massive real-world multi-modal data library serving oncology R&D. BioCorteX is already a strategic partner with Tempus, but Tempus is also a competitive data + AI platform in the same pharma-R&D customer segment.

Emerging players

• Lantern Pharma: AI-driven oncology drug development company using machine learning to identify responders and accelerate clinical development. Comparable focus on AI-driven oncology trial optimization, though smaller scale and more internal drug development orientation.
• Standigm: AI-driven drug discovery company using proprietary models to identify novel targets and drug candidates. Comparable as a Korean-origin AI platform targeting pharma partnerships, with adjacent workflow to Carbon Mirror's in-silico experimentation concept.
• GNS Healthcare: AI platform for causal analytics on patient data to inform drug development and clinical trial design. Comparable as a pharma R&D-focused AI platform using patient-level data to model treatment outcomes.
• Eagle Genomics: UK-based AI platform for microbiome and multi-omic data analytics serving consumer health, agritech, and pharma. Closely comparable as a microbiome-data-focused AI platform, though historically more diversified across non-pharma verticals.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioCorteX